These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20413296)

  • 1. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines.
    Sasada T; Komatsu N; Suekane S; Yamada A; Noguchi M; Itoh K
    Eur J Cancer; 2010 Jun; 46(9):1514-9. PubMed ID: 20413296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current status and future perspective of cancer vaccine development].
    Sasada T; Itoh K
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
    Mosolits S; Nilsson B; Mellstedt H
    Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in therapeutic cancer vaccines.
    Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
    Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cancer vaccines].
    Kyte JA
    Tidsskr Nor Laegeforen; 2006 Nov; 126(22):2969-73. PubMed ID: 17117197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
    Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
    J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roadmap to a better therapeutic tumor vaccine.
    Emens LA
    Int Rev Immunol; 2006; 25(5-6):415-43. PubMed ID: 17169782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A; Pandha H
    Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer vaccines: promise for the future or pipe dream?
    Mittendorf EA; Peoples GE; Singletary SE
    Cancer; 2007 Oct; 110(8):1677-86. PubMed ID: 17763371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer vaccines: between the idea and the reality.
    Finn OJ
    Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current developments with peptide-based human tumor vaccines.
    Khazaie K; Bonertz A; Beckhove P
    Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention.
    Vonderheide RH
    Discov Med; 2007 Aug; 7(39):103-8. PubMed ID: 18093471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP; Gates JD; Benavides LC; Hueman MT; Carmichael MG; Patil R; Craig D; Mittendorf EA; Stojadinovic A; Ponniah S; Peoples GE
    Cancer; 2008 Oct; 113(7):1666-75. PubMed ID: 18726994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.